Clinical challenges in the molecular characterization of circulating tumour cells in breast cancer

Por Lianidou, E S, Mavroudis, D, Georgoulias, V
Publicado em 2013

Comparison of EGFR and K-RAS gene status between primary tumours and corresponding metastases in NSCLC

Por Kalikaki, A, Koutsopoulos, A, Trypaki, M, Souglakos, J, Stathopoulos, E, Georgoulias, V, Mavroudis, D, Voutsina, A
Publicado em 2008

Salvage chemotherapy with high-dose leucovorin (LV) and 48-hour continuous infusion (CI) of 5-fluorouracil (5-FU) in combination with conventional doses of cyclophosphamide (CPM) i...

Por Kalbakis, K, Kouroussis, Ch, Kakolyris, S, Mavroudis, D, Souglakos, J, Agelaki, S, Vamvakas, L, Christodoulakis, M, Stylianou, K, Georgoulias, V
Publicado em 2001

Detection of cytokeratin-19 mRNA-positive cells in the peripheral blood and bone marrow of patients with operable breast cancer

Por Daskalaki, A, Agelaki, S, Perraki, M, Apostolaki, S, Xenidis, N, Stathopoulos, E, Kontopodis, E, Hatzidaki, D, Mavroudis, D, Georgoulias, V
Publicado em 2009

Clinical relevance of circulating CK-19mRNA-positive tumour cells before front-line treatment in patients with metastatic breast cancer

Por Androulakis, N, Agelaki, S, Perraki, M, Apostolaki, S, Bozionelou, V, Pallis, A, Kalbakis, K, Xyrafas, A, Mavroudis, D, Georgoulias, V
Publicado em 2012

BRAF mutations, microsatellite instability status and cyclin D1 expression predict metastatic colorectal patients’ outcome

Por Saridaki, Z, Papadatos-Pastos, D, Tzardi, M, Mavroudis, D, Bairaktari, E, Arvanity, H, Stathopoulos, E, Georgoulias, V, Souglakos, J
Publicado em 2010

Differential effect of adjuvant taxane-based and taxane-free chemotherapy regimens on the CK-19 mRNA-positive circulating tumour cells in patients with early breast cancer

Por Xenidis, N, Perraki, M, Apostolaki, S, Agelaki, S, Kalbakis, K, Vardakis, N, Kalykaki, A, Xyrafas, A, Kakolyris, S, Mavroudis, D, Georgoulias, V
Publicado em 2013

Correlation of BRCA1, TXR1 and TSP1 mRNA expression with treatment outcome to docetaxel-based first-line chemotherapy in patients with advanced/metastatic non-small-cell lung cance...

Por Papadaki, C, Tsaroucha, E, Kaklamanis, L, Lagoudaki, E, Trypaki, M, Tryfonidis, K, Mavroudis, D, Stathopoulos, E, Georgoulias, V, Souglakos, J
Publicado em 2011

Interaction of natural killer cells with MHC class II: reversal of HLA-DR1-mediated protection of K562 transfectant from natural killer cell-mediated cytolysis by brefeldin-A.

Por Jiang, Y Z, Couriel, D, Mavroudis, D A, Lewalle, P, Malkovska, V, Hensel, N F, Dermime, S, Molldrem, J, Barrett, A J
Publicado em 1996

A dose escalation and pharmacokinetic study of biweekly pegylated liposomal doxorubicin, paclitaxel and gemcitabine in patients with advanced solid tumours

Por Bozionelou, V, Vamvakas, L, Pappas, P, Agelaki, S, Androulakis, N, Kalykaki, A, Nikolaidou, M, Kentepozidis, N, Giassas, S, Marselos, M, Georgoulias, V, Mavroudis, D
Publicado em 2007

‘Classical’ but not ‘other’ mutations of EGFR kinase domain are associated with clinical outcome in gefitinib-treated patients with non-small cell lung cancer

Por Pallis, A G, Voutsina, A, Kalikaki, Ar, Souglakos, J, Briasoulis, E, Murray, S, Koutsopoulos, A, Tripaki, M, Stathopoulos, E, Mavroudis, D, Georgoulias, V
Publicado em 2007

Ribonucleotide reductase subunits M1 and M2 mRNA expression levels and clinical outcome of lung adenocarcinoma patients treated with docetaxel/gemcitabine

Por Souglakos, J, Boukovinas, I, Taron, M, Mendez, P, Mavroudis, D, Tripaki, M, Hatzidaki, D, Koutsopoulos, A, Stathopoulos, E, Georgoulias, V, Rosell, R
Publicado em 2008

A triplet combination with irinotecan (CPT-11), oxaliplatin (LOHP), continuous infusion 5-fluorouracil and leucovorin (FOLFOXIRI) plus cetuximab as first-line treatment in KRAS wt,...

Por Saridaki, Z, Androulakis, N, Vardakis, N, Vamvakas, L, Kabouraki, E, Kalbakis, K, Hatzidaki, D, Voutsina, A, Mavroudis, D, Georgoulias, V, Souglakos, J
Publicado em 2012

PKM2 as a biomarker for chemosensitivity to front-line platinum-based chemotherapy in patients with metastatic non-small-cell lung cancer

Por Papadaki, C, Sfakianaki, M, Lagoudaki, E, Giagkas, G, Ioannidis, G, Trypaki, M, Tsakalaki, E, Voutsina, A, Koutsopoulos, A, Mavroudis, D, Georgoulias, V, Souglakos, J
Publicado no Br J Cancer (2014)

FOLFOXIRI (folinic acid, 5-fluorouracil, oxaliplatin and irinotecan) vs FOLFIRI (folinic acid, 5-fluorouracil and irinotecan) as first-line treatment in metastatic colorectal cance...

Por Souglakos, J, Androulakis, N, Syrigos, K, Polyzos, A, Ziras, N, Athanasiadis, A, Kakolyris, S, Tsousis, S, Kouroussis, Ch, Vamvakas, L, Kalykaki, A, Samonis, G, Mavroudis, D, Georgoulias, V
Publicado em 2006

Second-line treatment with irinotecan plus cisplatin vs cisplatin of patients with advanced non-small-cell lung cancer pretreated with taxanes and gemcitabine: a multicenter random...

Por Georgoulias, V, Agelidou, A, Syrigos, K, Rapti, A, Agelidou, M, Nikolakopoulos, J, Polyzos, A, Athanasiadis, A, Tselepatiotis, E, Androulakis, N, Kalbakis, K, Samonis, G, Mavroudis, D
Publicado em 2005

A multicentre phase II trial of cabazitaxel in patients with advanced non-small-cell lung cancer progressing after docetaxel-based chemotherapy

Por Kotsakis, A, Matikas, A, Koinis, F, Kentepozidis, N, Varthalitis, I I, Karavassilis, V, Samantas, Ep, Katsaounis, P, Dermitzaki, E K, Hatzidaki, D, Mavroudis, D, Georgoulias, V
Publicado no Br J Cancer (2016)